Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edonentan SCHEMBL29742313 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL6641356 | 0.93 | EDNRA (0.86) | EDNRAEDNRB | |
| SCHEMBL26041260 | 0.89 | EDNRA (0.80) | EDNRAEDNRB | |
| SCHEMBL6641311 | 0.88 | EDNRB (1.00) | EDNRAEDNRB | |
| SCHEMBL13668944 | 0.86 | EDNRA (0.76) | EDNRAEDNRB | |
| SCHEMBL26552022 | 0.86 | EDNRA (0.76) | EDNRAEDNRB | |
| SCHEMBL6703895 | 0.83 | EDNRA (0.71) | EDNRAEDNRB | |
| SCHEMBL6641373 | 0.82 | EDNRB (1.00) | EDNRAEDNRB | |
| SCHEMBL6963011 | 0.81 | EDNRA (0.68) | EDNRAEDNRB | |
| SCHEMBL6641551 | 0.79 | EDNRB (0.83) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076948-A1 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | PERFUSE THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | claimed |
| WO-2025137005-A1 | METHODS OF PREPARING DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF OCULAR DISEASES | PERFUSE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025137007-A1 | METHODS OF PREPARING DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF OCULAR DISEASES | PERFUSE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250099435-A1 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | PERFUSE THERAPEUTICS, INC. | 2025-03-27 | — | — | US | claimed |
| WO-2024179362-A1 | METHODS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION SKELETAL SEQUELAE | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2024-09-06 | — | — | WO | claimed |
| WO-2024141048-A1 | METHODS FOR TREATING CORONAVIRUS INFECTIONS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2024-07-04 | — | — | WO | claimed |
| US-20240189288-A1 | TREATMENT OF GLAUCOMA USING ENDOTHELIN RECEPTOR ANTAGONISTS | PERFUSE THERAPEUTICS, INC. | 2024-06-13 | — | — | US | claimed |
| EP-4329810-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | Perfuse Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| US-20240058265-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | PERFUSE THERAPEUTICS, INC. | 2024-02-22 | — | — | US | claimed |
| US-11738007-B2 | Treatment of glaucoma using endothelin receptor antagonists | PERFUSE THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | claimed |
| WO-2002049630-A2 | METHOD FOR PREVENTING OR TREATING PAIN BY ADMINISTERING AN ENDOTHELIN ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-27 | — | — | WO | claimed |
| US-6313308-B1 | CONTACTING BORONIC ACID-SUBSTITUTED BENZENESULFONIC ACID WITH HALOBENZENE IN PRESENCE OF PALLADIUM CATALYST AND ALKALI METAL COMPOUND BASE; SALT FORMATION, CHLORINATION, COUPLING | BRISTOL-MYERS SQUIBB COMPANY | 2001-11-06 | — | — | US | claimed |
| US-6268388-B1 | ADMINISTERING A BIPHENYL SULFONAMIDE | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-31 | — | — | US | claimed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | claimed |
| EP-0996618-A4 | ENDOTHELIN ANTAGONISTS: N- 2'- (4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'- (3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2000-05-03 | — | — | EP | claimed |
| EP-0996618-A1 | ENDOTHELIN ANTAGONISTS: N- 2'- (4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'- (3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-03 | — | — | EP | claimed |
| US-6043265-A | TREATING HYPERTENSION, PULMONARY HYPERTENSION, BENIGN PROSTATIC HYPERTROPHY, MIGRAINE, UROGENITAL DISORDERS, ENDOTOXEMIA, ISCHEMIA, ATHEROSCLEROSIS, RESTENOSIS, SUBARACHNOID HEMORRHAGE, CONGESTIVE HEART FAILURE | BRISTOL-MYERS SQUIBB CO. (US) | 2000-03-28 | — | — | US | claimed |
| WO-1999010345-A1 | METHOD FOR PREVENTING OR TREATING ERECTILE DYSFUNCTION BY ADMINISTERING AN ENDOTHELIN ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1998033780-A1 | ENDOTHELIN ANTAGONISTS: N-[[2'-[ [(4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) [1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'-[(3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL)[1,1'-BIPHENYL]-2-SULFONAMIDE AND SALTS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998033781-A1 | METHOD FOR PREVENTING OR TREATING LOW RENIN HYPERTENSION BY ADMINISTERING AN ENDOTHELIN ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099435-A1 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | EDNRA, EDNRB, EDF1 | EDNRA 1/4885EDNRB 2/4885 |
| US-20240058265-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885 |
| US-20260076948-A1 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | EDNRA, EDNRB, STRA6 | EDNRA 1/4885EDNRB 2/4885 |
| US-11738007-B2 | Treatment of glaucoma using endothelin receptor antagonists | EDNRA, EDNRB, FLT1 | EDNRA 1/4885EDNRB 2/4885 |
| US-20240189288-A1 | TREATMENT OF GLAUCOMA USING ENDOTHELIN RECEPTOR ANTAGONISTS | EDNRA, EDNRB, FLT1 | EDNRA 1/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.